Tag: Humacyte
Humacyte submits Biologics License Application to FDA seeking approval of Human...
Humacyte today announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking approval of the Human...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental...
Humacyte announces positive top line results from Phase 2/3 trial of...
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
A...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrollment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular...
Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was...
Humacyte provides update on patients treated at front-line hospitals in Ukraine...
Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries....